Lilly breaks ground in Lebanon and adds $1.6 billion

Eli Lilly broke ground in 2023 on a new manufacturing campus in Lebanon, Indiana, part of the state's LEAP Research and Innovation District, and has since expanded its financial commitment to the site multiple times ^[1]. By May 2024, the company said it had more than doubled its investment there, raising the total from $3.7 billion to $9 billion through a new $5.3 billion commitment ^[1]. The site's exact spending history in April 2023, including the specific dollar figure tied to that period, is not spelled out in the available source, so the precise size of that earlier step is not yet confirmed here.

What is documented is the scale of what Lilly is building. The company says the Lebanon site sits on nearly 600 acres and, since groundbreaking, construction has spread across a large share of that land ^[1]. Lilly expects to begin producing medicines there toward the end of 2026, with production scaling up through 2028 ^[1]. The company describes the investment as the largest in Lilly's history and, it believes, the largest single investment in synthetic medicine active pharmaceutical ingredient (API) manufacturing in U.S. history ^[1].

The purpose of the expansion is to increase supply of API for tirzepatide, the active ingredient in Mounjaro, approved for type 2 diabetes, and Zepbound, approved for obesity ^[1]. Lilly says it began investing in manufacturing capacity in 2020, before either drug was approved, based on early research results for tirzepatide, in order to be ready once Mounjaro (2022) and Zepbound (2023) reached the market ^[1]. The company points to "strong demand" for these medicines as the reason more capacity is needed ^[1].

Job figures are also part of the announcement. The May 2024 commitment is expected to add 200 full-time jobs for engineers, scientists, operating personnel and lab technicians, bringing the site's projected workforce to about 900 full-time employees once fully operational ^[1]. Lilly also says the site's development will generate more than 5,000 construction jobs ^[1]. Indiana Governor Eric Holcomb and Lilly executives, including CEO David Ricks and Edgardo Hernandez, executive vice president and president of Lilly Manufacturing Operations, framed the project as both an economic development effort for Indiana and a step toward meeting patient demand ^[1].

Beyond Lebanon, Lilly says it has committed more than $18 billion since 2020 to build, upgrade, or acquire manufacturing sites in the U.S. and Europe, including locations in North Carolina, Ireland, and Germany, plus $1.2 billion in upgrades to existing Indianapolis facilities and the acquisition of a Wisconsin injectable manufacturing plant ^[1].

Why it matters for patients

For people currently prescribed Mounjaro or Zepbound, or those hoping to start one of these tirzepatide medicines, manufacturing capacity has been a persistent bottleneck tied to supply shortages. Lilly's stated goal in expanding the Lebanon site is to increase the amount of API available so more patients can access these treatments ^[1]. However, the source does not say when patients might notice changes in supply, since Lilly does not expect the Lebanon facility to begin producing medicine until toward the end of 2026, with output increasing through 2028 ^[1]. That means any effect on drug availability tied to this specific site is still years away, not immediate.

The announcement also does not address pricing, insurance coverage, or how supply from this new site will be distributed once it comes online. Those remain open questions not addressed in the available source.

What happens next

According to Lilly, production at the Lebanon site is expected to begin toward the end of 2026, with manufacturing operations scaling up through 2028 ^[1]. The company also says a workforce training center, tied to partnerships with Purdue University and Ivy Tech Community College, is planned as part of the broader LEAP district development, though a completion date is not given in the source ^[1].